BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 30655185)

  • 1. Early-onset of symptoms and clinical course of Pompe disease associated with the c.-32-13 T > G variant.
    Herbert M; Case LE; Rairikar M; Cope H; Bailey L; Austin SL; Kishnani PS
    Mol Genet Metab; 2019 Feb; 126(2):106-116. PubMed ID: 30655185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant.
    Rairikar MV; Case LE; Bailey LA; Kazi ZB; Desai AK; Berrier KL; Coats J; Gandy R; Quinones R; Kishnani PS
    Mol Genet Metab; 2017 Nov; 122(3):99-107. PubMed ID: 28951071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pompe disease in Austria: clinical, genetic and epidemiological aspects.
    Löscher WN; Huemer M; Stulnig TM; Simschitz P; Iglseder S; Eggers C; Moser H; Möslinger D; Freilinger M; Lagler F; Grinzinger S; Reichhardt M; Bittner RE; Schmidt WM; Lex U; Brunner-Krainz M; Quasthoff S; Wanschitz JV
    J Neurol; 2018 Jan; 265(1):159-164. PubMed ID: 29181627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.
    Montagnese F; Barca E; Musumeci O; Mondello S; Migliorato A; Ciranni A; Rodolico C; De Filippi P; Danesino C; Toscano A
    J Neurol; 2015; 262(4):968-78. PubMed ID: 25673129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic implications of pathogenic variant types in Pompe disease.
    Viamonte MA; Filipp SL; Zaidi Z; Gurka MJ; Byrne BJ; Kang PB
    J Hum Genet; 2021 Nov; 66(11):1089-1099. PubMed ID: 33972680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late Onset Pompe Disease with Novel Mutations and Atypical Phenotypes.
    Chawla T; Preethish-Kumar V; Polavarapu K; Vengalil S; Bardhan M; Puri R; Verma J; Christopher R; Supriya M; Nashi S; Prasad C; Nadeesh B; Nalini A
    J Neuromuscul Dis; 2022; 9(2):261-273. PubMed ID: 34864681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe disease.
    Kishnani PS; Gibson JB; Gambello MJ; Hillman R; Stockton DW; Kronn D; Leslie ND; Pena LDM; Tanpaiboon P; Day JW; Wang RY; Goldstein JL; An Haack K; Sparks SE; Zhao Y; Hahn SH;
    Genet Med; 2019 Nov; 21(11):2543-2551. PubMed ID: 31086307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype.
    Kroos MA; Pomponio RJ; Hagemans ML; Keulemans JL; Phipps M; DeRiso M; Palmer RE; Ausems MG; Van der Beek NA; Van Diggelen OP; Halley DJ; Van der Ploeg AT; Reuser AJ
    Neurology; 2007 Jan; 68(2):110-5. PubMed ID: 17210890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pompe disease ascertained through The Lantern Project, 2018-2021: Next-generation sequencing and enzymatic testing to overcome obstacles to diagnosis.
    Sniderman King L; Pan Y; Nallamilli BRR; Hegde M; Jagannathan L; Ramachander V; Lucas A; Markind J; Colzani R
    Mol Genet Metab; 2023 May; 139(1):107565. PubMed ID: 37087815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity of whole exome sequencing in detecting infantile- and late-onset Pompe disease.
    Mori M; Haskell G; Kazi Z; Zhu X; DeArmey SM; Goldstein JL; Bali D; Rehder C; Cirulli ET; Kishnani PS
    Mol Genet Metab; 2017 Dec; 122(4):189-197. PubMed ID: 29122469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Childhood Pompe disease: clinical spectrum and genotype in 31 patients.
    van Capelle CI; van der Meijden JC; van den Hout JM; Jaeken J; Baethmann M; Voit T; Kroos MA; Derks TG; Rubio-Gozalbo ME; Willemsen MA; Lachmann RH; Mengel E; Michelakakis H; de Jongste JC; Reuser AJ; van der Ploeg AT
    Orphanet J Rare Dis; 2016 May; 11(1):65. PubMed ID: 27189384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of Later-Onset Pompe Disease Identified Through Newborn Screening.
    Lee NC; Chang KL; In 't Groen SLM; de Faria DOS; Huang HJ; Pijnappel WWMP; Hwu WL; Chien YH
    J Pediatr; 2022 May; 244():139-147.e2. PubMed ID: 34995642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rare Variants in Autophagy and Non-Autophagy Genes in Late-Onset Pompe Disease: Suggestions of Their Disease-Modifying Role in Two Italian Families.
    Napolitano F; Bruno G; Terracciano C; Franzese G; Palomba NP; Scotto di Carlo F; Signoriello E; De Blasiis P; Navarro S; Gialluisi A; Melone MAB; Sampaolo S; Esposito T
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33807278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A genetic modifier of symptom onset in Pompe disease.
    Bergsma AJ; In 't Groen SLM; van den Dorpel JJA; van den Hout HJMP; van der Beek NAME; Schoser B; Toscano A; Musumeci O; Bembi B; Dardis A; Morrone A; Tummolo A; Pasquini E; van der Ploeg AT; Pijnappel WWMP
    EBioMedicine; 2019 May; 43():553-561. PubMed ID: 30922962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of enzyme replacement therapy on bone density in late onset Pompe disease.
    Avanti M; Martin A; Columbres RC; Mozaffar T; Kimonis V
    Mol Genet Metab; 2023 Nov; 140(3):107644. PubMed ID: 37515933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early clinical phenotype of late onset Pompe disease: Lessons learned from newborn screening.
    Huggins E; Holland M; Case LE; Blount J; Landstrom AP; Jones HN; Kishnani PS
    Mol Genet Metab; 2022 Mar; 135(3):179-185. PubMed ID: 35123877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ACE I/D polymorphism does not explain heterogeneity of natural course and response to enzyme replacement therapy in Pompe disease.
    Kuperus E; van der Meijden JC; In 't Groen SLM; Kroos MA; Hoogeveen-Westerveld M; Rizopoulos D; Martinez MYN; Kruijshaar ME; van Doorn PA; van der Beek NAME; van der Ploeg AT; Pijnappel WWMP
    PLoS One; 2018; 13(12):e0208854. PubMed ID: 30532252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and Genetic Aspects of Juvenile Onset Pompe Disease.
    Holzwarth J; Minopoli N; Pfrimmer C; Smitka M; Borrel S; Kirschner J; Muschol N; Hartmann H; Hennermann JB; Neubauer BA; Hobbiebrunken E; Husain RA; Hahn A
    Neuropediatrics; 2022 Feb; 53(1):39-45. PubMed ID: 34852371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late onset Pompe Disease in India - Beyond the Caucasian phenotype.
    Puri RD; Setia N; N V; Jagadeesh S; Nampoothiri S; Gupta N; Muranjan M; Bhat M; Girisha KM; Kabra M; Verma J; Thomas DC; Biji I; Raja J; Makkar R; Verma IC; Kishnani PS
    Neuromuscul Disord; 2021 May; 31(5):431-441. PubMed ID: 33741225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Late onset Pompe disease: an analysis of 19 patients from Mexico].
    Sánchez-Sánchez LM; Martinez-Montoya V; Sandoval-Pacheco R; Torres-Octavo B; Anaya-Castro DM; Padilla-de la Torre O; Arellano-Valdez CA; Ávila-Rejón CA; Aguilar-Juárez PA; Espino-Pluma M; González-Santillanes Cruz A; Kazakova E; Martinez-Segovia RI; Olmos-Morfin D; Radillo-Díaz PF; Solís-Sánchez I; Vázquez Del Mercado-Espinosa M; Villarroel-Cortés CE; Velarde-Félix JS
    Rev Neurol; 2022 Sep; 75(5):103-108. PubMed ID: 35880963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.